Abstract: A computer readable media, a method, and a system registering a third party application providing an available communication system between a local user and a remote user identity, storing information related to the available communication system in a first database, obtaining contact information for the remote user identity from the third party application, determining a communication type for the third party application, pairing the remote user identity with a contact, and updating a graphical representation of contact information.

Abstract: Disclosed herein are modified human interleukin-2 (hIL-2) proteins, human antibody molecules, or antigen-binding fragments thereof, that immunospecifically bind to human programmed cell death protein-1 (hPD-1), and immunoconjugates comprising the same.

Abstract: An apparatus for irrigating the vas deferens in connection with a vasectomy reversal is described. The apparatus comprises a fluid delivery device having a first portion that connects to the vas deferens, the fluid delivery device connecting such that a catheter tip inserts into the vas deferens and is held in stable position relative thereto and such that fluid enters the vas deferens through the catheter tip.

Abstract: An optimized lead generation, management, communication, and tracking system is disclosed. In particular, the system may allow for the automation of business, clinical, and computing activities for a practice, organization, business, or other entity. The system utilizes a comprehensive and robust online portal with digital software functions and digital communications capabilities to accomplish tasks that are traditionally performed by personnel or unable to be performed by personnel. For example, the system is capable of attracting, screening, and scheduling patients for procedures to be performed at a medical practice. Additionally, the system may communicate with a patient before and after a medical procedure, track patient outcomes after a patient undergoes a procedure, and calculate key performance metrics and indicators specific to the entity and/or the procedure.

Abstract: Provided is an antibody for treating a cancer, more specifically, an anti-CD43 antibody binding to an extracellular domain of CD43, compositions for treating a cancer or inhibiting a cancer stem cell comprising the antibody as an active ingredient, and methods for screening an agent of inhibiting a cancer stem cell.

Abstract: An optimized lead generation, management, communication, and tracking system is disclosed. In particular, the system may allow for the automation of business, clinical, and computing activities for a practice, organization, business, or other entity. The system utilizes a comprehensive and robust online portal with digital software functions and digital communications capabilities to accomplish tasks that are traditionally performed by personnel or unable to be performed by personnel. For example, the system is capable of attracting, screening, and scheduling patients for procedures to be performed at a medical practice. Additionally, the system may communicate with a patient before and after a medical procedure, track patient outcomes after a patient undergoes a procedure, and calculate key performance metrics and indicators specific to the entity and/or the procedure.

Abstract: Here, the inventors describe methods and compositions for targeting a TLR agonist to the tumor cell or stroma. Aspects of the disclosure relate to a polypeptide comprising a tumor targeting agent operatively linked to p(Man-TLR). Also disclosed are compositions and methods for treating cancer in a subject comprising administration of the polypeptide comprising the tumor targeting agent linked to p(Man-TLR) to the subject.

Abstract: Methods for cancer treatment include administering to a cancer patient an anti-CD38 antibody-attenuated human IFN alpha-2b construct and lenalidomide or pomalidomide. Tumors that may be treated according to these methods include tumors which comprise CD-38 expressing tumor cells, including B-cell lymphoma, multiple myeloma, non-Hodgkin's lymphoma, chronic myelogenous leukemia, chronic lymphocytic leukemia, and acute lymphocytic leukemia.

Abstract: Antibodies that specifically bind to CD38, as well as constructs comprising such antibodies fused to attenuated interferon alpha-2B proteins are provided. Anti-CD38-attenuated interferon alpha-2b fusion constructs may be used to inhibit proliferation in cancerous cells that express both CD38 and the receptor for IFN-alpha2b, as well as to induce apoptosis in such cells. Inhibition of proliferation and induction of apoptosis in cancerous cells may serve as the basis for the treatment of the underlying cancer.

Abstract: The present invention provides a polypeptide construct comprising a peptide or polypeptide signaling ligand linked to an antibody or antigen binding portion thereof which binds to a cell surface-associated antigen, wherein the ligand comprises at least one amino acid substitution or deletion which reduces its potency on cells lacking expression of said antigen.

Abstract: Provided is an antibody for treating a cancer, more specifically, an anti-CD43 antibody binding to an extracellular domain of CD43, compositions for treating a cancer or inhibiting a cancer stem cell comprising the antibody as an active ingredient, and methods for screening an agent of inhibiting a cancer stem cell.

Abstract: Apparatus are disclosed for coupling integrated segments of an assemblage. The coupler apparatus includes a carrier connectable to one segment and slidably receiving another segment and has an elongate slot defined at one wall portion of a cavity therein. A restraint includes a conic wedge receivable in the carrier and has an actuator arm angularly extending from the wedge that is receivable through the elongate slot of the carrier.

Abstract: Provided is an antibody for treating a cancer, more specifically, an anti-CD43 antibody binding to an extracellular domain of CD43, compositions for treating a cancer or inhibiting a cancer stem cell comprising the antibody as an active ingredient, and methods for screening an agent of inhibiting a cancer stem cell.

Abstract: An apparatus for irrigating the vas deferens in connection with a vasectomy reversal is described. The apparatus comprises a fluid delivery device having a first portion that connects to the vas deferens, the fluid delivery device connecting such that a catheter tip inserts into the vas deferens and is held in stable position relative thereto and such that fluid enters the vas deferens through the catheter tip.

Abstract: An apparatus for irrigating the vas deferens in connection with a vasectomy reversal is described. The apparatus comprises a fluid delivery device having a first portion that connects to the vas deferens, the fluid delivery device connecting such that a catheter tip inserts into the vas deferens and is held in stable position relative thereto and such that fluid enters the vas deferens through the catheter tip.

Abstract: Methods for cancer treatment include administering to a cancer patient an anti-CD38 antibody-attenuated human IFN alpha-2b construct and lenalidomide or pomalidomide. Tumors that may be treated according to these methods include tumors which comprise CD-38 expressing tumor cells, including 8-cell lymphoma, multiple myeloma, non-Hodgkin's lymphoma, chronic myelogenous leukemia, chronic lymphocytic leukemia, and acute lymphocytic leukemia.

Abstract: Methods for cancer treatment include administering to a cancer patient an anti-CD38 antibody-attenuated human IFN alpha-2b construct and lenalidomide or pomalidomide. Tumors that may be treated according to these methods include tumors which comprise CD-38 expressing tumor cells, including B-cell lymphoma, multiple myeloma, non-Hodgkin's lymphoma, chronic myelogenous leukemia, chronic lymphocytic leukemia, and acute lymphocytic leukemia.

Abstract: Apparatus are disclosed for coupling integrated segments of an assemblage. The coupler apparatus includes a carrier connectable to one segment and slidably receiving another segment and has an elongate slot defined at one wall portion of a cavity therein. A restraint includes a conic wedge receivable in the carrier and has an actuator arm angularly extending from the wedge that is receivable through the elongate slot of the carrier.

Abstract: Provided is an antibody for treating a cancer, more specifically, an anti-CD43 antibody binding to an extracellular domain of CD43, compositions for treating a cancer or inhibiting a cancer stem cell comprising the antibody as an active ingredient, and methods for screening an agent of inhibiting a cancer stem cell.

Abstract: Antibodies that specifically bind to CD38, as well as constructs comprising such antibodies fused to attenuated interferon alpha-2B proteins are provided. Anti-CD38-attenuated interferon alpha-2b fusion constructs may be used to inhibit proliferation in cancerous cells that express both CD38 and the receptor for IFN-alpha2b, as well as to induce apoptosis in such cells. Inhibition of proliferation and induction of apoptosis in cancerous cells may serve as the basis for the treatment of the underlying cancer.